-
Sponsored by InventaVítor Palmela Fidalgo of Inventa reviews three years of Unified Patent Court jurisprudence, examining emerging approaches to claim interpretation, prosecution history, doctrine of equivalents, and prior use -
Sponsored by Società Italiana Brevetti (SIB)Società Italiana Brevetti (SIB) speak about how the EU rules on Supplementary Protection Certificates will be clarified in Halozyme CJEU case
-
Sponsored by Bird & BirdThe singer is among an increasing number of celebrities using trademark law to counter AI-generated impersonation. Ann Henry, Sarah McMullen, and Isabel Humburg of Bird & Bird (Ireland) examine evolving challenges for brand owners
-
Sponsored by PurpleVine IPChinese enterprises are mastering the ‘rules of the game’ and leveraging patents to strengthen their competitive position, explains Li Weina of PurpleVine IP
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Abhishek Nangia of RNA, Technology and IP Attorneys explain how the ruling clarifies the limits on the use of personal names in pharmaceutical trademarks
-
Sponsored by Patrinos & KilimirisChristos Xagoraris of Patrinos & Kilimiris analyses a Greek court ruling confirming that earlier local distinctive signs can prevail over later trademarks within their territory
-
Sponsored by IP MarchHuanfang Wu and Stephen Yang from IP March speak about the overview of the examination practice of "Same-Day Dual Filing" applications in China
-
Sponsored by IP MarchHuanfang Wu and Stephen Yang from IP March speak about the overview of the examination practice of "Same-Day Dual Filing" applications in China
-
Sponsored by INLEXIgor Charles of INLEX analyses a Paris court ruling that clarifies when alterations to genuine luxury goods constitute trademark infringement and misleading practices
-
Sponsored by INLEXPravir Palayathan of INLEX explains how the ruling strengthens protection for well-known marks and clarifies parasitism and unfair competition in disputes
-
Sponsored by HANOL ClassHankyul IP & LawMin Son of Hanol IP & Law outlines the new system’s key mechanisms and implications for evidence gathering in civil litigation, with a particular focus on technology-related disputes
-
Sponsored by CASCAS explains how intellectual property intelligence enables biologics companies to reduce R&D risk, extend market exclusivity, and unlock commercial value in an increasingly competitive pharmaceutical landscape
